Satjit Adlakha, DO
Interventional Cardiology · Pascagoula, MSNPI 1356550594
Payments from drug & device makers
What this record shows
The money is spread across several categories — other (44.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 28 manufacturers reported payments, led by Angiodynamics, Inc. at 45.0% of the total. 2025 is the largest year on record at $6,382, more than ten times the $631 reported in 2019.
Across 314 payments — averaging $60.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$9K
- Boston Scientific$6K
- Abbott$858
- Merck$636
- Medtronic$444
- Johnson & Johnson$401
- plus $3K from 22 others
What the payments were for
- Travel & lodging$3,37818%
- Food & beverage$7,14838%
- Gifts$750%
- Other$8,33344%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 6 | $8,512 |
| Boston Scientific | 70 | $5,552 |
| Abbott | 42 | $858 |
| Merck | 31 | $636 |
| Medtronic(2 entities) | 12 | $444 |
| Johnson & Johnson | 25 | $401 |
| AstraZeneca | 22 | $362 |
| Philips North America LLC | 10 | $356 |
| Abiomed | 12 | $222 |
| Boehringer Ingelheim | 11 | $188 |
| Esperion Therapeutics, Inc. | 10 | $163 |
| Bayer | 9 | $146 |
| Novartis | 7 | $138 |
| Pfizer | 6 | $136 |
| Chiesi USA, Inc. | 5 | $133 |
| W. L. Gore & Associates, Inc. | 4 | $115 |
| Sanofi-aventis U.S. LLC | 4 | $111 |
| E.r. Squibb & Sons, L.L.C. | 7 | $111 |
| Biotronik Inc. | 5 | $77 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $73 |
| Vifor Pharma, Inc. | 3 | $56 |
| Amgen | 2 | $31 |
| Bard Peripheral Vascular, Inc. | 1 | $26 |
| Braemar Manufacturing, LLC | 1 | $24 |
| Amarin Pharma, Inc. | 1 | $19 |
| Lexicon Pharmaceuticals, Inc. | 1 | $19 |
| Vivaquant Inc, Dba Rhythm Express | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auryon Laser System 100-120 Vac$8,474
- VersaCross Access Solution$3,705
- AVVIGO Guidance System$250
- AVEIR$153
- (BS0) Mechanical Atherectomy$132
- IN.PACT Admiral$110
- GENERAL VASCULAR INTERVENTION$106
How this compares
$18,934 in reported general payments places this provider in the 70th percentile of 65 interventional cardiology providers in Mississippi.
See all interventional cardiology providers in Mississippi →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 441 | $485,694 |
| EntrestoSacubitril/Valsartan | 307 | $367,463 |
| XareltoRivaroxaban | 204 | $218,101 |
| JardianceEmpagliflozin | 112 | $102,755 |
| BrilintaTicagrelor | 59 | $49,901 |
| FarxigaDapagliflozin Propanediol | 51 | $47,162 |
| VerquvoVericiguat | 17 | $25,656 |
| Repatha SureclickEvolocumab | 20 | $21,146 |
| NexlizetBempedoic Acid/Ezetimibe | 21 | $11,086 |
| VascepaIcosapent Ethyl | 12 | $10,064 |
| Potassium Chloride | 287 | $6,523 |
| Pyridostigmine Bromide | 108 | $5,562 |
| Amiodarone Hcl | 165 | $4,665 |
| Atorvastatin Calcium | 501 | $4,574 |
| Losartan Potassium | 495 | $4,173 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $136 | $485,694441 claims |
| NovartisEntresto | $138 | $367,463307 claims |
| Johnson & JohnsonXarelto | $401 | $218,101204 claims |
| Boehringer IngelheimJardiance | $188 | $102,755112 claims |
| AstraZenecaBrilinta, Farxiga | $362 | $97,063110 claims |
| MerckVerquvo | $636 | $25,65617 claims |
| Esperion Therapeutics, Inc.Nexlizet | $163 | $11,08621 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 65 interventional cardiology providers in Mississippi.
Other interventional cardiology in Pascagoula
- John WinscottJackson$482K
- William CrowderJackson$331K
- Foluso FakoredeCleveland$298K
- James BennettJackson$160K
- Abdul BahroFlowood$132K
- Brett BennettJackson$126K
- John KingColumbus$74K
- Michael CunninghamBiloxi$45K
- Alejandro Lemor FerrandJackson$37K
- David YoungJackson$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.